# Innate Pharma SA: financial statements, quarterly

IPHA · Nasdaq · CIK 1598599 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ipha.md) · [Financials](/companies/ipha/financials.md) · [Filings](/companies/ipha/filings.md) · [Insiders](/companies/ipha/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ipha/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2016-12-31) | period not labelled (2017-12-31) | period not labelled (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [176](/filings/0001171843-20-002847.md) | [99.4](/filings/0001628280-21-007629.md) | [152](/filings/0001628280-22-008197.md) | [203](/filings/0001628280-23-010946.md) | [137](/filings/0001598599-24-000020.md) | [104](/filings/0001598599-25-000042.md) | [84.2](/filings/0001598599-26-000005.md) | [70.6](/filings/0001598599-26-000005.md) | [66.4](/filings/0001598599-26-000005.md) | [28.1](/filings/0001598599-26-000005.md) |
| Current assets | $m | not reported | [138](/filings/0001171843-20-002847.md) | [320](/filings/0001628280-21-007629.md) | [238](/filings/0001628280-22-008197.md) | [173](/filings/0001628280-23-010946.md) | [138](/filings/0001598599-24-000020.md) | [140](/filings/0001598599-25-000042.md) | [148](/filings/0001598599-26-000005.md) | [85.7](/filings/0001598599-26-000005.md) | [46.7](/filings/0001598599-26-000005.md) |
| Total assets | $m | not reported | [255](/filings/0001171843-20-002847.md) | [451](/filings/0001628280-21-007629.md) | [401](/filings/0001628280-22-008197.md) | [307](/filings/0001628280-23-010946.md) | [267](/filings/0001598599-24-000020.md) | [199](/filings/0001598599-25-000042.md) | [175](/filings/0001598599-26-000005.md) | [111](/filings/0001598599-26-000005.md) | [62.7](/filings/0001598599-26-000005.md) |
| Current liabilities | $m | not reported | [73.9](/filings/0001171843-20-002847.md) | [197](/filings/0001628280-21-007629.md) | [122](/filings/0001628280-22-008197.md) | [45.5](/filings/0001628280-23-010946.md) | [79.9](/filings/0001598599-24-000020.md) | [41.3](/filings/0001598599-25-000042.md) | [39.6](/filings/0001598599-26-000005.md) | [33.0](/filings/0001598599-26-000005.md) | [36.6](/filings/0001598599-26-000005.md) |
| Shareholders' equity | $m | [86.2](/filings/0001171843-20-002847.md) | [99.4](/filings/0001628280-21-007629.md) | [167](/filings/0001628280-22-008197.md) | [217](/filings/0001628280-23-010946.md) | [156](/filings/0001598599-24-000020.md) | [107](/filings/0001598599-25-000042.md) | [54.2](/filings/0001598599-26-000005.md) | [51.9](/filings/0001598599-26-000005.md) | [8.8](/filings/0001598599-26-000005.md) | [(21.7)](/filings/0001598599-26-000005.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 93,719,323 at 2025-12-31, from the cover of the [20-F filed 2026-04-01](/filings/0001598599-26-000005.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.